These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35568782)

  • 1. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
    He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
    Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells.
    Ohno K; Shibata T; Ito KI
    Cancer Sci; 2022 Sep; 113(9):3193-3210. PubMed ID: 35723021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
    Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression.
    Fujita K; Yamada M; Morishita A; Ono M; Himoto T; Kobara H; Masaki T
    Biochem Pharmacol; 2024 Aug; 226():116321. PubMed ID: 38815631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
    Hu B; Zou T; Qin W; Shen X; Su Y; Li J; Chen Y; Zhang Z; Sun H; Zheng Y; Wang CQ; Wang Z; Li TE; Wang S; Zhu L; Wang X; Fu Y; Ren X; Dong Q; Qin LX
    Cancer Res; 2022 Oct; 82(20):3845-3857. PubMed ID: 36066408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma.
    Fan FM; Fleishman JS; Chen J; Chen ZS; Dong HH
    Drug Discov Today; 2024 Aug; 29(8):104069. PubMed ID: 38936692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
    Ao J; Chiba T; Shibata S; Kurosugi A; Qiang N; Ma Y; Kan M; Iwanaga T; Sakuma T; Kanzaki H; Kanayama K; Kojima R; Kusakabe Y; Nakamura M; Saito T; Nakagawa R; Kondo T; Ogasawara S; Suzuki E; Muroyama R; Kato J; Mimura N; Kanda T; Maruyama H; Kato N
    Biochem Biophys Res Commun; 2021 Apr; 549():171-178. PubMed ID: 33676186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma.
    Baxter MA; Glen H; Evans TR
    Future Oncol; 2018 Aug; 14(20):2021-2029. PubMed ID: 29783903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
    Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
    Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma.
    Miyazaki K; Morine Y; Xu C; Nakasu C; Wada Y; Teraoku H; Yamada S; Saito Y; Ikemoto T; Shimada M; Goel A
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR activation limits the response of liver cancer to lenvatinib.
    Jin H; Shi Y; Lv Y; Yuan S; Ramirez CFA; Lieftink C; Wang L; Wang S; Wang C; Dias MH; Jochems F; Yang Y; Bosma A; Hijmans EM; de Groot MHP; Vegna S; Cui D; Zhou Y; Ling J; Wang H; Guo Y; Zheng X; Isima N; Wu H; Sun C; Beijersbergen RL; Akkari L; Zhou W; Zhai B; Qin W; Bernards R
    Nature; 2021 Jul; 595(7869):730-734. PubMed ID: 34290403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma.
    Iseda N; Itoh S; Toshida K; Tomiyama T; Morinaga A; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Yoshizumi T; Mori M
    Cancer Sci; 2022 Jul; 113(7):2272-2287. PubMed ID: 35466502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy.
    Qin Y; Han S; Yu Y; Qi D; Ran M; Yang M; Liu Y; Li Y; Lu L; Liu Y; Li Y
    Liver Int; 2024 Aug; 44(8):1808-1831. PubMed ID: 38700443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.